Table 3.
Multivariate analyses of OS and BCSS for the MBC after PSM.
| OS HR | 95% CI/p value | BCSS HR | 95% CI/p value | |
|---|---|---|---|---|
| Age, years | ||||
| 20–30 | 1.00 | 1.00 | ||
| 31–40 | 1.277 | 0.49–3.32; p = 0.62 | 1.22 | 0.47–3.20; p = 0.68 |
| 41–50 | 1.752 | 0.71–4.34; p = 0.23 | 1.42 | 0.57–3.53; p = 0.45 |
| 51–60 | 1.780 | 0.72–4.38; p = 0.21 | 1.46 | 0.59–3.60; p = 0.42 |
| 61–70 | 2.149 | 0.87–5.28; p = 0.10 | 1.55 | 0.63–3.84; p = 0.34 |
| 71–80 | 3.360 | 1.36–8.28; p < 0.01 | 1.83 | 0.74–4.58; p = 0.19 |
| 81–90 | 5.215 | 2.09–13.02; p < 0.01 | 2.43 | 0.94–6.25; p = 0.07 |
| Race/ethnicity | ||||
| American Indian/Alaska Native | 1.00 | 1.00 | ||
| Asian or Pacific Islander | 0.59 | 0.24–1.44; p = 0.25 | 0.42 | 0.15–1.15; p = 0.09 |
| Blank | 0.72 | 0.31–1.68; p = 0.45 | 0.59 | 0.23–1.49; p = 0.26 |
| White | 0.62 | 0.27–1.43; p = 0.26 | 0.52 | 0.21–1.30; p = 0.16 |
| Unknown | 0.36 | 0.04–3.04; p = 0.35 | 0.55 | 0.06–4.85; p = 0.55 |
| Insurance status | ||||
| Insured | 1.00 | 1.00 | ||
| Medicaid | 1.05 | 0.81–1.37; p = 0.67 | 0.93 | 0.68–1.27; p = 0.65 |
| Uninsured/unknown | 1.13 | 0.96–1.33; p = 0.15 | 1.05 | 0.85–1.30; p = 0.66 |
| Tumor grade | ||||
| Undifferentiated | 1.00 | 1.00 | ||
| Poorly differentiated | 0.78 | 0.57–1.06; p = 0.11 | 0.71 | 0.49–1.01; p = 0.06 |
| Moderately differentiated | 0.67 | 0.46–0.98; p = 0.04 | 0.43 | 0.26–0.71; p < 0.01 |
| Well differentiated | 0.57 | 0.30–1.08; p = 0.08 | 0.49 | 0.20–1.19; p = 0.11 |
| Unknown | 0.68 | 0.48–0.96; p = 0.03 | 0.53 | 0.34–0.81; p < 0.01 |
| Tumor size | ||||
| ≤10 mm | 1.00 | 1.00 | ||
| ≤20 mm | 1.70 | 0.96–2.30; p = 0.07 | 1.28 | 0.57–2.90; p = 0.56 |
| ≤30 mm | 2.53 | 1.47–4.36; p < 0.01 | 2.93 | 1.36–6.28; p < 0.01 |
| ≤40 mm | 3.07 | 1.74–5.41; p < 0.01 | 3.46 | 1.58–7.60; p < 0.01 |
| ≤50 mm | 3.35 | 1.87–6.00; p < 0.01 | 4.25 | 1.91–9.48; p < 0.01 |
| >50 mm | 7.93 | 4.56–13.77; p < 0.01 | 9.30 | 4.31–20.07; p < 0.01 |
| Lymph node state | ||||
| 0 | 1.00 | 1.00 | ||
| 1–3 | 1.56 | 1.28–1.90; p < 0.01 | 1.85 | 1.47–2.33; p < 0.01 |
| 4–9 | 2.36 | 1.76–3.16; p < 0.01 | 2.72 | 1.96–3.77; p < 0.01 |
| ≥10 | 3.41 | 2.34–4.97; p < 0.01 | 4.00 | 2.65–6.03; p < 0.01 |
| Risk stratification | ||||
| Low risk | 1.00 | 1.00 | ||
| Intermediate risk | 1.979 | 1.59–2.46; p < 0.01 | 2.564 | 1.85–3.55; p < 0.01 |
| High risk | 4.652 | 3.58–6.05; p < 0.01 | 6.384 | 4.42–9.22; p < 0.01 |
| Others | 4.554 | 3.43–6.01; p < 0.01 | 6.683 | 4.54–9.85; p < 0.01 |
| ER status | ||||
| Negative | 1.00 | 1.00 | ||
| Positive | 0.83 | 0.64–1.06; p = 0.13 | 0.85 | 0.63–1.15; p = 0.29 |
| PR status | ||||
| Negative | 1.00 | 1.00 | ||
| Positive | 0.92 | 0.70–1.21; p = 0.53 | 1.09 | 0.79–1.50; p = 0.61 |
| Treatment with chemotherapy | ||||
| Yes | 1.00 | 1.00 | ||
| No | 1.37 | 1.16–1.63; p < 0.01 | 1.13 | 0.90–1.43; p = 0.28 |
| Post-mastectomy radiotherapy | ||||
| Yes | 1.00 | 1.00 | ||
| No | 1.44 | 1.24–1.66; p < 0.01 | 1.42 | 1.18–1.70; p < 0.01 |
MBC, metaplastic breast cancer; ER, estrogen receptor; PR, progesterone receptor; PSM, propensity score-matched; PMRT, post-mastectomy radiotherapy; OS, overall survival; BCSS, breast cancer specific survival.
According to the pathological stage of lymph nodes, we divided lymph node state into four groups by the number of lymph node metastasis.